Proove Biosciences, which sold dubious DNA tests to predict addiction risk, sells off assets as CEO departs amid criminal probe
By Charles Piller,
STAT
| 08. 31. 2017
Proove Biosciences, a formerly high-flying genetic testing firm whose science and business practices have been challenged by experts and former employees, has been placed into court-ordered receivership for “restructuring and asset sale,” according to the company’s founder and former CEO.
Proove’s founder, Brian Meshkin, said in an interview on Thursday that he no longer works at Proove, which rang up $28 million in revenue last year. Meshkin blamed the company’s fall on investigative articles published by STAT last December and February. Those articles quoted experts who expressed deep doubts about the company’s scientific claims that it could predict a patient’s likelihood of becoming addicted to opioids. “Hogwash” was the assessment of Dr. Mary Jeanne Kreek, a leading researcher on genetic links to addiction at Rockefeller University.
STAT’s investigations also described business practices — including coercing patients to take unnecessary genetic tests — that former Proove employees and outside experts described as unethical and possibly illegal.
In June, agents from the FBI and Department of Health and Human Services agents raided Proove’s offices in Irvine, Calif. to collect truckloads of documents...
Related Articles
A Review of Exposed by Becky McClain
“Do not get lost in a sea of despair. Be hopeful, be optimistic. Our struggle is not the struggle of a day, a week, a month, or a year, it is the struggle of a lifetime. Never, ever be afraid to make some noise and get in good trouble, necessary trouble.”
— John Lewis
Becky McClain became famous when she successfully sued Pfizer, one of the very largest pharmaceutical and biotech companies. She...
By Josie Ensor, The Times | 12.09.2025
A fertility start-up that promises to screen embryos to give would-be parents their “best baby” has come under fire for a “misuse of science”.
Nucleus Genomics describes its mission as “IVF for genetic optimisation”, offering advanced embryo testing that allows...
By staff, Japan Times | 12.04.2025
Japan plans to introduce a ban with penalties on implanting a genome-edited fertilized human egg into the womb of a human or another animal amid concerns over "designer babies."
A government expert panel broadly approved a proposal, including the ban...
By David Jensen, The California Stem Cell Report | 12.11.2025
California’s stem cell and gene therapy agency today approved spending $207 million more on training and education, sidestepping the possibility of using the cash to directly support revolutionary research that has been slashed and endangered by the Trump administration.
Directors...
